Tykerb - 2007 FDA approvals

Drug: Tykerb (lapatinib)
Indication: Metastatic breast cancer
Company: GlaxoSmithKline
Approval Date: March 13, 2007

Scoop: The FDA gave its approval to Tykerb for metastatic breast cancer in combination with Xeloda. Tykerb is also in trials for metastatic brain cancer. Tykerb has an advantage over the blockbuster Herceptin because it is administered in pill form while Herceptin is injected. And data supports that Tykerb in combination with Xeloda is more effective that a treatment consisting only of Xeloda.

More news:
FDA approves Tykerb for breast cancer. Report

Tykerb - 2007 FDA approvals

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i